Bolt Biotherapeutics is developing its novel Boltbody(TM) platform for cancer immunotherapy therapy that consists of Immune-Stimulating Antibody Conjugates (ISAC). Boltbodies are demonstrating tumor eradication and the establishment of immunological memory in preclinical tumor models following systemic administration.
With a unique pathogen-targeted approach, Entasis developed a clinical and pre-clinical pipeline of first- and potentially best-in-class antibiotic medicines. These include small-molecule programs to treat serious multidrug-resistant Gram-negative infections that are public health threats, including Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacteriaceae, and a single dose oral therapy for susceptible and drug-resistant Neisseria gonorrhoeae. In 2015, Entasis Therapeutics was spun out from AstraZeneca, with all rights to AstraZeneca’s industry-leading discovery and early development small-molecule anti-infective portfolio. Entasis is headquartered in Waltham, MA.
A clinical stage biopharmaceutical company with the goal of curing cancer by developing targeted alpha therapeutics. They see targeted alpha therapeutics as the next generation of radiation therapy. At Fusion, they are pushing the boundaries of science to create innovative cancer treatments. They believe that targeted alpha therapeutics represent the evolution of radiopharmaceuticals which holds great promise to improve the lives of patients with cancer.
Inozyme is a biotechnology company committed to developing novel medicines for the treatment of rare metabolic diseases of calcification. The company was founded in 2016 with technology licensed from Yale University.
Iterum is a clinical-stage pharmaceutical company dedicated to developing differentiated oral and IV anti-infective agents aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. Iterum’s lead development program is sulopenem, an IV and orally bioavailable broad spectrum carbapenem antibiotic. Iterum Therapeutics Limited is led by former management team members of Durata Therapeutics (subsequently sold to Actavis) and is headquartered in Dublin, Ireland.
Karuna Therapeutics is a clinical-stage company targeting muscarinic cholinergic receptors for the treatment of psychosis and cognitive impairment across central nervous system (CNS) disorders.
Oculis is a clinical stage ocular therapeutics company focusing on innovative topical treatments (eye drops) for both back and front of the eye diseases. The company's treatments are based on its proprietary Solubilizing Nanoparticle (SNP) technology, which makes it easier to formulate drugs into eye drops and also enhances their penetration into the deeper tissues of the eye. Oculis’ lead program is OC-118, an SNP based formulation of dexamethasone being developed for Diabetic Macular Edema, one of the leading causes of blindness in diabetics. Oculis is led by experienced former executives from leading eyecare company Alcon, and is headquartered in Switzerland.
SutroVax is a vaccine platform and development company whose mission is to deliver best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent deadly infectious diseases. The company is leveraging an exclusive license to Sutro Biopharma’s Xpress CF cell-free protein synthesis platform to develop vaccines with heightened immunity and broader protection than can be attained with existing vaccine platforms. SutroVax’s lead program is a potentially best-in-class pneumococcal conjugate vaccine (PCV) to prevent invasive pneumococcal disease. SutroVax is headquartered in Foster City, CA.